ArticleAntiviral research2018
Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model.
Article in Antiviral research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 55 citations in OpenAlex.
- Infant Infection With Respiratory Syncytial Virus Genotypes and Subsequent Childhood Asthma Risk.The Journal of infectious diseases · 2026Article
- RSV vaccine development: advances and fusion protein-focused strategies.Frontiers in immunology · 2026Review
- Article
- Review
- Article
- Dual-Function Adjuvant Cyclosporin A: Enhancing RSV-Specific Humoral Immunity via Treg-Driven B-Cell Activation.Vaccines · 2025Article
- Review
- Review
- Layer-by-Layer Microparticle Vaccines Containing a S177Q Point Mutation in the Central Conserved Domain of the RSV G Protein Improves Immunogenicity.Viral immunology · 2025Article
- Structures of respiratory syncytial virus G bound to broadly reactive antibodies provide insights into vaccine design.Scientific reports · 2025Article
- Article
- Fc-FcγR interactions during infections: From neutralizing antibodies to antibody-dependent enhancement.Immunological reviews · 2024Review
- Article
- Article
- Exosome-mediated regulation of inflammatory pathway during respiratory viral disease.Virology journal · 2024Review
- Article
- Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine.Frontiers in immunology · 2023Article
- New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus.Infection and drug resistance · 2023Review
- RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses.NPJ vaccines · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
RSV continues to be a high priority for vaccine and antiviral drug development. Unfortunately, no safe and effective RSV vaccine is available and treatment options are limited. Over the past decade, several studies have focused on the role of RSV G protein on viral entry, viral neutralization, and RSV-mediated pathology. Anti-G murine monoclonal antibody (mAb) 131-2G treatment has been previously shown to reduce weight loss, bronchoalveolar lavage (BAL) cell number, airway reactivity, and Th2-type cytokine production in RSV-infected mice more rapidly than a commercial humanized monoclonal antibody (mAb) against RSV F protein (Palivizumab). In this study, we have tested two human anti-RSV G mAbs, 2B11 and 3D3, by both prophylactic and therapeutic treatment for RSV in the BALB/c mouse model. Both anti-G mAbs reduced viral load, leukocyte infiltration and IFN-γ and IL-4 expression in cell-free BAL supernatants emphasizing the potential of anti-G mAbs as anti-inflammatory and antiviral strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.